Home › Funds › VIKING GLOBAL INVESTORS LP › BBIO
VIKING GLOBAL INVESTORS LP position in BBIO
BRIDGEBIO PHARMA INC · Health Care
VIKING GLOBAL INVESTORS LP reported holding 9,949,219 shares of BBIO (BRIDGEBIO PHARMA INC) in its Q2 2026 13F filing — a position valued at US$741.0M, representing 2.11% of its reported portfolio and ranking #15 among its reported holdings. VIKING GLOBAL INVESTORS LP has disclosed BBIO holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How VIKING GLOBAL INVESTORS LP's BBIO position evolved
VIKING GLOBAL INVESTORS LP first disclosed a stake in BBIO in Q3 2023 at 25,120,991 shares (US$662.4M). The position peaked in Q4 2025 at 14,393,934 shares, worth US$1.10B. Across 12 filings, VIKING GLOBAL INVESTORS LP increased the stake 0 time(s), trimmed it 6 time(s) and left it unchanged 5 time(s). The most recent filing (Q2 2026) shows 9,949,219 shares valued at US$741.0M — a reduction of -1,893,215 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 25.12M | $662.44M | New |
| Q4 2023 | 25.12M | $1.01B | Hold |
| Q1 2024 | 25.12M | $776.74M | Hold |
| Q2 2024 | 25.12M | $636.31M | Hold |
| Q3 2024 | 25.12M | $639.58M | Hold |
| Q4 2024 | 25.12M | $689.32M | Hold |
| Q1 2025 | 22.06M | $762.45M | Reduce |
| Q2 2025 | 18.56M | $801.22M | Reduce |
| Q3 2025 | 15.98M | $829.89M | Reduce |
| Q4 2025 | 14.39M | $1.10B | Reduce |
| Q1 2026 | 11.84M | $879.42M | Reduce |
| Q2 2026 | 9.95M | $741.02M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BBIO and 13F data
BBIO (BRIDGEBIO PHARMA INC) is a Health Care company. 47 other funds we track also report a position in BBIO — the largest reported positions include Jupiter Topco LLC (US$1.05B), Janus Henderson Group (US$978.6M), Farallon Capital Management (US$800.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BBIO
- Jupiter Topco LLC 14.11M sh · $1.05B · Q2 2026
- Janus Henderson Group 13.18M sh · $978.61M · Q1 2026
- Farallon Capital Management 10.74M sh · $800.14M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 10.74M sh · $800.14M · Q2 2026
- Viking Global Investors 9.95M sh · $741.02M · Q2 2026
- Aisling Capital Management LP 4.59M sh · $341.83M · Q2 2026
- SC US (TTGP), LTD. 1.86M sh · $138.56M · Q2 2026
- STEELHEAD PARTNERS LLC 70.00M sh · $124.78M · Q2 2026
- CAPSTONE INVESTMENT ADVISORS, LLC 69.87M sh · $124.49M · Q2 2026
- Frazier Life Sciences Management, L.P. 1.55M sh · $115.31M · Q2 2026
- FRONTIER CAPITAL MANAGEMENT CO LLC 1.37M sh · $102.27M · Q2 2026
- Hood River Capital Management LLC 1.35M sh · $100.36M · Q2 2026
More on VIKING GLOBAL INVESTORS LP
FAQ
How long has VIKING GLOBAL INVESTORS LP held BBIO?
VIKING GLOBAL INVESTORS LP has disclosed BBIO holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is VIKING GLOBAL INVESTORS LP's current position in BBIO?
As of Q2 2026, VIKING GLOBAL INVESTORS LP holds 9.95M shares of BBIO (BRIDGEBIO PHARMA INC), valued at $741.02M, representing 2.11% of its reported portfolio and ranking #15.
Has VIKING GLOBAL INVESTORS LP been buying or selling BBIO?
In the latest 13F filing (Q2 2026), VIKING GLOBAL INVESTORS LP reduced its position in BBIO. The position peaked in Q4 2025 at 14.39M shares.
Which other funds hold BBIO?
Other major institutional holders of BBIO include Jupiter Topco LLC, Janus Henderson Group, Farallon Capital Management, among 47 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.